drugset / Trial / NCT00743379

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors

NCT00743379

Phase 1/2 Completed 71 enrolled Threshold Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if TH-302, in combination with A) Gemcitabine, or B) Docetaxel or C) Pemetrexed methotrexate, are safe and effective in the treatment of Pancreatic Cancer, Castrate-resistant Prostate Cancer, and Non-small Cell Lung Cancer, respectively.

Timeline

Start
2008-08
Primary completion
2013-07
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Evofosfamide Other / unclassified Intravenous